SynthesisScientific reports2019
The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses.
Synthesis in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Prevalence and epidemiology of hepatitis C in Uzbekistan: results from a population-based serosurvey, 2022.IJID regions · 2026Article
- Awareness, knowledge, and practices related to hepatitis B and hepatitis C in the Republic of Uzbekistan-Results from a population-based survey, 2022.BMC public health · 2026Article
- Hepatitis B and C landscape in Uzbekistan: epidemiological patterns revealed in a study of 1 040 000 people.European journal of public health · 2025Article
- Seroprevalence of hepatitis B, hepatitis C, and HIV in pregnant women attending a tertiary care hospital in Mogadishu, Somalia, 2017-2021.BMC infectious diseases · 2025Article
- Sex-related differences in patients with chronic hepatitis C infection treated with direct-acting antiviral drugs.World journal of hepatology · 2025Article
- Microelimination of Hepatitis C in Thailand, Phetchabun Model: Progress, Challenges, and Future Directions.Journal of clinical medicine · 2025Review
- Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.BMJ open gastroenterology · 2025Article
- Comparison of registered and survey-based modes of HIV transmission in 2021-2023: Cross-sectional study in the Kyrgyz Republic.PloS one · 2025Article
- Global burden and trends of viral hepatitis among women of childbearing age from 1990 to 2021.Frontiers in microbiology · 2025Article
- Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population.BMC public health · 2024Article
- The Changing Epidemiology of Viral Hepatitis in a Post-Soviet Country-The Case of Kyrgyzstan.Pathogens (Basel, Switzerland) · 2023Article
- Prevalence of Viral Hepatitis B, C, and D in Kazakhstan.TheScientificWorldJournal · 2022Article
- Hepatitis C Co-infection in People Living With HIV-Epidemiologic Differences Between Men Who Have Sex With Men MSM and Non-MSM.Frontiers in public health · 2022Article
- Association of Hepatitis C Virus Replication with the Catecholamine Biosynthetic Pathway.Viruses · 2021Article
- Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan.PloS one · 2021Article
- Article
- The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses.Royal Society open science · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective was to delineate hepatitis C virus (HCV) epidemiology in countries of Central Asia (CA), specifically Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. A systematic review was conducted guided by the Cochrane Collaboration Handbook, and reported using PRISMA guidelines. Meta-analyses were performed using DerSimonian-Laird random-effects models with inverse variance weighting. Random-effects meta-regression analyses were performed on general population studies. The systematic review identified a total of 208 HCV prevalence measures. No incidence or Turkmenistan studies were identified. Meta-analyses estimated HCV prevalence among the general population at 0.7% (95%CI: 0.7-0.8%) in Kazakhstan, 2.0% (95%CI: 1.7-2.4%) in Kyrgyzstan, 2.6% (95%CI: 1.7-3.6%) in Tajikistan, and 9.6 (95%CI: 5.8-14.2%) in Uzbekistan. Across CA, the pooled mean prevalence was 13.5% (95%CI: 10.9-16.4%) among non-specific clinical populations, 31.6% (95%CI: 25.8-37.7%) among populations with liver-related conditions, and 51.3% (95%CI: 46.9-55.6%) among people who inject drugs. Genotypes 1 (52.6%) and 3 (38.0%) were most frequent. Evidence was found for statistically-significant differences in prevalence by country, but not for a temporal decline in prevalence. CA is one of the most affected regions by HCV infection with Uzbekistan enduring one of the highest prevalence levels worldwide. Ongoing HCV transmission seems to be driven by injecting drug use and healthcare exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.